Clinical Trials Logo

Primary Biliary Cholangitis clinical trials

View clinical trials related to Primary Biliary Cholangitis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05239468 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Start date: March 21, 2022
Phase: Phase 2
Study type: Interventional

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).

NCT ID: NCT05104853 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Start date: January 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.

NCT ID: NCT05014672 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

TRANSFORM
Start date: February 14, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).

NCT ID: NCT04594694 Active, not recruiting - Clinical trials for Primary Biliary Cholangitis

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Start date: October 2, 2019
Phase: Phase 2
Study type: Interventional

Study to evaluate the efficacy, safety, and tolerability of investigational drug obeticholic acid (OCA) in combination with the investigational drug bezafibrate (BZF) in participants with Primary Biliary Cholangitis (PBC).